BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-8@catalystbrief.girapphe.com
DTSTAMP:20261117T024426Z
LAST-MODIFIED:20261117T024426Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Readout: AskGene Pharma\, Inc. — ASKB589 [Dec 2026]
DESCRIPTION:Phase 3 primary completion: ASKB589 with CAPOX and PD-1 inhibit
 or in advanced or metastatic GC/GEJ adenocarcinoma.\nSource: https://clini
 caltrials.gov/study/NCT06206733\nhttps://catalystbrief.girapphe.com/e/8?la
 ng=en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/8?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
